A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 195 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Starving cancer into submission January 30, 2023 EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel August 26, 2025 Combination Chemo Helps People with Leiomyosarcoma Live Longer October 2, 2024 Preparación para el fin de la emergencia de salud pública (PHE)... April 3, 2023 Load more HOT NEWS Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus... Is AI Ready to Play a Leading Role in Colorectal Cancer... Touching a nerve: How neuroscience could advance our understanding of cancer Exercise of Any Intensity Found to Provide Similar Benefits in Cancer...
